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HUMAN PAPILLOMAVIRUS TYPE 16 (HPV16) E6/E7-SPECIFIC CYTO-
TOXIC T LYMPHOCYTES (CTLS) FOR IMMUNOTHERAPY OF HPV-ASSOCI-
ATED MALIGNANCIES
Ramos, C.A.1, Narala, N.1, Leen, A.M.1, Gerdemann, U.1,
Anderson, M.L.2, Sturgis, E.M.3, Savoldo, B.1, Heslop, H.E.1,
Brenner, M.K.1, Rooney, C.M.1 1Baylor College of Medicine, Houston,
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Vaccines prevent HPV-associated cancer (Ca), but their use as
therapy for established Ca has been disappointing. Although the tar-
get tumor cells express the viral E6 and E7 antigens (Ag), patients’
immune responses against virally infected cells are limited, even after
active immunization, likely due to negative environmental cues that
block initial tumor cell recognition and subsequent T cell (TC) ac-
tivation and expansion in vivo. We postulated that ex vivo stimula-
tion of patient TCs in an immunologically favorable milieu would
allow us to reactivate tumor-directed CTLs.
We studied 67 patients withHPV+Ca (16 cervical and 51 oropha-
ryngeal, OPCa). To investigate the presence of HPV16 E6- and E7-
specific TCs (HPV-TCs) in blood, wemeasured the g-IFNELISpot
responses of TCs stimulated by monocyte-derived dendritic cells
(DCs) loaded with pepmixes (peptide libraries of 15-mers overlap-
ping by 11 aa) spanning E6 and E7. Although 75% of OPCa are
HPV16+, we initially found no evidence of E6/E7-reactive T cells
in the patients tested. Because HPV-TCs from these patients may
be anergized by their tumors, we postulated that potent Ag present-
ing strategies might be required for reactivation. In other studies, we
have found that in vitro stimulation of T cells in the presence of DCs
and IL-6, -7, -12 and -15 can induce responses to poorly immuno-
genic Ag. We therefore tested this approach in patients with
HPV+ Ca, and found we could successfully reactivate HPV-TCs
in 8/16 cervical and 32/51 OPCa patients.
Given it is difficult to obtain large numbers of DCs, we expanded
these HPV-TCs to clinically useful numbers by substituting patient
B-cell blasts (BBs) as APCs, which we made by culturing autologous
PBMCs with IL-4 on a CD40L+ feeder layer. Stimulation of DC-
stimulated HPV-TCs by E6/E7 pepmix-loaded BBs further ex-
panded HPV-TC lines (3.8 6 1.5/round), whose phenotype is
summarized in the Table. The epitopes recognized by the HPV-
TCs mapped to E6 aa 49-71, 77-91 and 125-143, and E7 aa 1-19
and 73-87. These cells achieved dose-dependent specific killing of
E6/E7+ target cells (specific lysis up to 45-61% vs. 0-8% in controls,
40:1 E:T ratio). Thus, we have generated true CTLs.
Table. Phenotypic analysis of HPV-specific cell lines
Marker % ± SDCD3 97.5 ± 3.4
CD4 36.7 ± 28.2
CD8 49.4 ± 27.0
CD56 (CD3 negative) 1.5 ± 0.9All cell lines are almost exclusively composed of T cells, with a variable
proportion of CD4+ and CD8+ cells, displaying a predominantly effector
memory phenotype (CD45RA–, CD45RO+, CD62L– and CCR7–). There
are minimal CD3– NK cells. Vb-chain TCR repertoire analysis established
polyclonality.
In summary, we have developed a system that allows the robust
generation of HPV-directed CTLs from the blood of patients with
HPV16+ Ca, and shown that they recognize specific epitopes in tu-
mor-associated Ag. Our lines have the potential to be used for adop-
tive cellular immunotherapy of HPV+ Ca.
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NOVEL THERAPY WITH INTERFERON-a IN COMBINATION WITH DONOR
LYMPHOCYTE INFUSION FOR HIGH RISK ACUTE LEUKEMIA PATIENTS
WHO RELAPSED AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Tang, X., Zhou, Q., Jin, Z., Fu, Z., Ye, C., Shi, X., Sun, A., Wu, D. The
First Affiliated Hospital of SoochowUniversity, Jiangsu Institute of Hema-
tology, Suzhou, Jiangsu Province, China
Objective: In order to improve the graft versus leukemia (GVL) ef-
fect of DLI, we investigated the efficacy and safety of combininginterferon-a with DLI (aDLI) in patients with high risk acute leuke-
mia (AL) who relapsed after allo-HSCT, and compared the efficacy,
toxicity and leukemia free survival (LFS) of aDLI and traditional do-
nor lymphocyte infusion (tDLI) in our transplantation center.
Methods: Sixteen acute leukemia patients were treated with inter-
feron-a-2b therapy at a dose of 3106U/day subcutaneously for 5
days followed by G-CSF mobilized donor peripheral stem cell infu-
sion. (termed with ‘‘aDLI’’). The median duration of IFN-a treat-
ment was 17 (5-50) days, and the median CD3+ cells dose was
9.25107/kg (4-20107/kg). In parallel, we retrospectively analyzed
the results of tDLI for 14 AL patients with hematologic relapse post
allo-HSCT treated in the same period in our center, and compared
the efficacy, toxicity and LFS of tDLI with aDLI.
Results: Patients treated on the aDLI protocol included 9 ALL and
7 AML, with a median age of 26.5 years. Fourteen of 16 patients had
high risk AL. The median relapse time was 5.5 (range, 1-25) months
post transplant. Salvage chemotherapy was administrated in 7 pa-
tients before aDLI, with only 3 patients achieved CR. The overall
CR rate for aDLI protocol was 75% (12/16), with CR rate of
aDLI alone at 66.7% (6/9). The median time from aDLI to bone
marrow CR was 7 (6-14) days, and the median time to molecular
CR (MCR) and full donor chemerism (median level was 96.3%) in
responsive patients were 2 weeks post DLI. With a median follow-
up of 5.5 (range, 1-34) months, 7 patients were alive with durable
molecular CR. Two-year LFSwas 50%.Treatment related toxicities
included episode of fever, GVHD and myelosuppression. The tDLI
group had similar demographic characteristics with disease subtypes,
transplant and relapse history. Compared to tDLI, the aDLI proto-
col had higher CR rate (75.0% vs 14.3%, p5 0.001), faster response
(median time to obtain BMCRwere 7 days), and significant better 2-
year LFS (50.0% vs 7.1%, p 5 0.05). Importantly, there was no
significant difference between the two groups with respect to the in-
cidence of pancytopenia (53.8% vs 75%, p.0.05) and treatment re-
lated mortality (18.8% vs 7.1%, p.0.05).
Conclusion: IFN-a-2b in combination with DLI appears to induce
rapid anddurable remissions inhigh risk acute leukemiapatientswho re-
lapsed following allo-HSCT, with acceptable treatment-related toxicity.
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SALVAGE T CELL THERAPY FOR THERAPY RESISTANT VIRAL DISEASES
AFTER STEM CELL TRANSPLANTATION
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Mattsson, J.1,2 1Karolinska University Hospital, Stockholm, Sweden;
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Epstein-Barr virus (EBV), cytomegalovirus (CMV) and adenoviral
reactivations are frequent complications after allogeneic SCT be-
cause of a lack of T cell control due to extensive immunosuppression.
Cytotoxic T lymphocytes (CTLs) that recognize viral antigens are
themost important immune effector mechanism controlling the per-
sistent viral infections.
First-line treatment for viral reactivation is dose reduction of the im-
munosuppressive drugs and/or anti-viral therapy. For PTLD this is
followed by rituximab (anti-CD20 monoclonal antibody). Despite
these multiple treatment strategies, the l mortality from drug-resistant
viremia after SCT is still considerable. Another treatment approach is
adoptive transfer of virus specific CTLs from the donor. The standard
method of adoptive T cell immunotherapy is laborious and time-con-
suming and is often too late to be administrated to the patient.
We have developed a clinical separation protocol for virus specific
CTLs based on labeling with multimeric complexes containing re-
combinant HLA molecules together with virus derived peptides. By
combining this labeling technique with a secondary magnetic sorting
wehavemanaged toget a high purity of specificCTLs.This high purity
diminish the risk of creatingGVHDin the recipient even if the adoptive
transfer of cells is done in an allogeneic or haplo-identical setting.
We first used this protocol in an 18 year old patient with life-
threatening PTLD. The patient developed an EBV associated lym-
phoma involving lungs, liver and both kidneys and also showed
extremely high EBV titers in blood. It was decided to give her
EBV specific CTLs from her mother. 2 months after the given
EBV specific CTL infusion the EBV associated lymphoma was in
complete regression. After this we have further successfully treated
seven patients with life threatening viral disease (Adeno, CMV and
EBV) with good efficacy.We could see a clinical and immunological
